MEP32308A - Pharmaceutical composition containing histone deacetylase inhibitor - Google Patents

Pharmaceutical composition containing histone deacetylase inhibitor

Info

Publication number
MEP32308A
MEP32308A MEP-323/08A MEP32308A MEP32308A ME P32308 A MEP32308 A ME P32308A ME P32308 A MEP32308 A ME P32308A ME P32308 A MEP32308 A ME P32308A
Authority
ME
Montenegro
Prior art keywords
histone deacetylase
deacetylase inhibitor
pharmaceutical composition
composition containing
containing histone
Prior art date
Application number
MEP-323/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Osamu Nakanishi
Tatsuo Sugawara
Hideyuki Migita
Yasuhiro Matsuba
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MEP32308A publication Critical patent/MEP32308A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
MEP-323/08A 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor MEP32308A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003148073 2003-05-26
PCT/JP2004/007562 WO2004103369A1 (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor
YUP-2005/0884A RS20050884A (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Publications (1)

Publication Number Publication Date
MEP32308A true MEP32308A (en) 2010-10-10

Family

ID=33475383

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-323/08A MEP32308A (en) 2003-05-26 2004-05-26 Pharmaceutical composition containing histone deacetylase inhibitor

Country Status (27)

Country Link
US (1) US20070098816A1 (es)
EP (1) EP1626719A1 (es)
JP (1) JP2006526031A (es)
KR (1) KR100938712B1 (es)
CN (2) CN101322707A (es)
AR (1) AR045318A1 (es)
AU (1) AU2004241873C1 (es)
BR (1) BRPI0410959A (es)
CA (4) CA2634709A1 (es)
CL (1) CL2004001278A1 (es)
CO (1) CO5660262A2 (es)
CR (1) CR8163A (es)
CU (1) CU23490B7 (es)
EC (1) ECSP056253A (es)
IL (1) IL171941A0 (es)
ME (1) MEP32308A (es)
MX (1) MXPA05012345A (es)
NO (1) NO20055417L (es)
NZ (1) NZ543591A (es)
PE (1) PE20050206A1 (es)
RS (1) RS20050884A (es)
RU (1) RU2322971C2 (es)
TW (1) TW200505424A (es)
UA (1) UA81499C2 (es)
UY (1) UY28330A1 (es)
WO (1) WO2004103369A1 (es)
ZA (1) ZA200509515B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
ES2344899T3 (es) 2003-09-25 2010-09-09 Astellas Pharma Inc. Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
US7446126B2 (en) * 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
EP1712552A1 (en) * 2005-04-11 2006-10-18 INDENA S.p.A. Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel
KR20150008926A (ko) * 2005-03-11 2015-01-23 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는 히스톤 데아세틸라제 억제제
WO2006102557A2 (en) 2005-03-22 2006-09-28 The President And Fellows Of Harvard College Treatment of protein degradation disorders
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
MX2008010462A (es) * 2006-02-14 2009-04-17 Harvard College Inhibidores de histona desacetilasa.
AU2007248656B2 (en) 2006-05-03 2013-04-04 Dana-Farber Cancer Institute, Inc. Histone deacetylase and tubulin deacetylase inhibitors
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
AU2007340129B2 (en) * 2006-12-26 2012-02-02 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
WO2009079375A1 (en) * 2007-12-14 2009-06-25 Georgetown University Histone deacetylase inhibitors
WO2010011296A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
NZ591387A (en) * 2008-08-29 2012-03-30 Bayer Pharma AG N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
US8841308B2 (en) 2008-12-19 2014-09-23 Vertex Pharmaceuticals Incorporated Pyrazin-2-amines useful as inhibitors of ATR kinase
US20120034302A1 (en) * 2009-02-11 2012-02-09 Liangping Yu Particulate composition and the method of making the same
WO2010125462A2 (en) * 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
WO2010144371A1 (en) * 2009-06-08 2010-12-16 Gilead Colorado, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
UA110196C2 (uk) * 2009-08-25 2015-12-10 Абраксіс Байосайєнс, Елелсі Комбінована терапія композиціями наночастинок таксану і інгібіторами хеджхог
EP2569313A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
ES2627820T3 (es) 2011-09-13 2017-07-31 Pharmacyclics, Inc. Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y usos de las mismas
US9035053B2 (en) 2011-09-30 2015-05-19 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of ATR kinase
SG11201401095YA (en) * 2011-09-30 2014-04-28 Vertex Pharma Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
WO2013085902A1 (en) * 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
LT2833973T (lt) 2012-04-05 2018-02-12 Vertex Pharmaceuticals Incorporated Junginiai, tinkami naudoti kaip atr kinazės inhibitoriai, ir jų kombinuotas gydymas
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
CA2903473A1 (en) 2013-03-12 2014-10-09 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
WO2014141129A2 (en) * 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
EA201592012A8 (ru) * 2014-02-21 2018-10-31 Общество С Ограниченной Ответственностью "Биолаб 612" Применение флагеллина для улучшенной химиотерапии
WO2016044138A1 (en) 2014-09-17 2016-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
JP3354090B2 (ja) 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
AP2001002109A0 (en) * 1998-09-25 2001-03-31 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.
KR100812972B1 (ko) * 1999-04-27 2008-03-13 미쯔비시 웰 파마 가부시키가이샤 간질환 예방/치료제
CA2386876A1 (en) * 1999-11-10 2001-05-17 Warner-Lambert Company Combination chemotherapy
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
JP2003137866A (ja) * 2001-11-01 2003-05-14 Sankyo Co Ltd フェニレンジアミン誘導体

Also Published As

Publication number Publication date
CU23490B7 (es) 2010-02-23
PE20050206A1 (es) 2005-03-26
JP2006526031A (ja) 2006-11-16
EP1626719A1 (en) 2006-02-22
AU2004241873C1 (en) 2009-01-22
RU2005140570A (ru) 2006-06-10
NZ543591A (en) 2009-09-25
ZA200509515B (en) 2006-07-26
IL171941A0 (en) 2006-04-10
BRPI0410959A (pt) 2006-07-04
MXPA05012345A (es) 2006-02-08
UA81499C2 (en) 2008-01-10
AU2004241873B2 (en) 2008-05-08
WO2004103369A1 (en) 2004-12-02
CA2527191A1 (en) 2004-12-02
CN101322707A (zh) 2008-12-17
CR8163A (es) 2006-07-14
ECSP056253A (es) 2006-10-25
CO5660262A2 (es) 2006-07-31
CN1794991A (zh) 2006-06-28
CA2634709A1 (en) 2004-12-02
TW200505424A (en) 2005-02-16
RU2322971C2 (ru) 2008-04-27
CL2004001278A1 (es) 2005-05-06
NO20055417L (no) 2005-12-19
UY28330A1 (es) 2004-12-31
CA2634766A1 (en) 2004-12-02
AR045318A1 (es) 2005-10-26
US20070098816A1 (en) 2007-05-03
CA2634765A1 (en) 2004-12-02
RS20050884A (en) 2008-04-04
KR100938712B1 (ko) 2010-01-25
AU2004241873A1 (en) 2004-12-02
AU2004241873B8 (en) 2008-05-29
NO20055417D0 (no) 2005-11-16
KR20060009371A (ko) 2006-01-31

Similar Documents

Publication Publication Date Title
MEP32308A (en) Pharmaceutical composition containing histone deacetylase inhibitor
NO20055216L (no) Nye hydroksamater som terapeutiske midler
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
NO20044135L (no) Piperazinyl-, piperidinyl- og morfolinylderivater som nye inhibitorer av histon-deacetylase
NO20044146L (no) Karbonylaminoderivater som nye inhibitorer av histon-deacetylase
EA200700143A1 (ru) Производные замещенного пропенилпиперазина в качестве новых ингибиторов гистондеацетилазы
NO20044444L (no) Benzamidderivater nyttige som histondeacetylase inhibitorer
CY1126110T1 (el) Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6
AR042851A1 (es) Acidos hidroxamicos inhibidores de histona desacetilasa
EA200701970A1 (ru) Гидроксаматы как ингибиторы гистондеацетилазы и содержащие их фармацевтические композиции
AR117655A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal
MX342041B (es) Formulacion farmaceutica para inhibidores de histona desacetilasa.
SV2006002109A (es) Una composicion farmaceutica antimicobacteriana
ATE373636T1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
EP4136085A4 (en) 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF
EP4110780A4 (en) COMPOUNDS DERIVED FROM 1,3,4-OXADIAZOLE USED AS HISTONE DEACETYLASE 6 INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
EA201170950A1 (ru) Новая комбинация активных ингредиентов, содержащая нестероидное противовоспалительное лекарственное средство и производное колхикозида
EA201992296A1 (ru) Производные хиноксалина и пиридопиразина в качестве ингибиторов pi3k-бета
TH81162A (th) สารผสมทางเภสัชกรรมที่มีตัวยับยั้งฮิสโตนดีอะซีทิลเลส
PE20212078A1 (es) Inhibidor de mpges 1 para el tratamiento de dolor de osteoartritis
TH81162B (th) สารผสมทางเภสัชกรรมที่มีตัวยับยั้งฮิสโตนดีอะซีทิลเลส
PE20040532A1 (es) Formulacion medicamentosa a base de fexofenadina
NO20044224L (no) Sulfonylaminoderivater som nye inhibitorer av histon-deacetylase